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Abstract
Background: The randomized controlled trial (RCT) is considered the gold standard study design to inform
decisions about the effectiveness of interventions. However, a common limitation is inadequate reporting of the
applicability of the intervention and trial results for people who are “socially disadvantaged” and this can affect
policy-makers’ decisions. We previously developed a framework for identifying health-equity-relevant trials, along
with a reporting guideline for transparent reporting. In this study, we provide a descriptive assessment of health-
equity considerations in 200 randomly sampled equity-relevant trials.
Methods: We developed a search strategy to identify health-equity-relevant trials published between 2013 and
2015. We randomly sorted the 4316 records identified by the search and screened studies until 100 individually
randomized (RCTs) and 100 cluster randomized controlled trials (CRTs) were identified. We developed and pilot-
tested a data extraction form based on our initial work, to inform the development of our reporting guideline for
equity-relevant randomized trials.
Results: In total, 39 trials (20%) were conducted in a low- and middle-income country and 157 trials (79%) in a
high-income country focused on socially disadvantaged populations (78% CRTs, 79% RCTs). Seventy-four trials (37%)
reported a subgroup analysis across a population characteristic associated with disadvantage (25% CRT, 49% RCTs),
with 19% of included studies reporting subgroup analyses across sex, 9% across race/ethnicity/culture, and 4%
across socioeconomic status. No subgroup analyses were reported for place of residence, occupation, religion,
education, or social capital. One hundred and forty-one trials (71%) discussed the applicability of their results to one
or more socially disadvantaged populations (68% of CRT, 73% of RCT).
Discussion: In this set of trials, selected for their relevance to health equity, data that were disaggregated for
socially disadvantaged populations were rarely reported. We found that even when the data are available,
opportunities to analyze health-equity considerations are frequently missed. The recently published equity
extension of the Consolidated Reporting Standards for Randomized Trials (CONSORT-Equity) may help improve
delineation of hypotheses related to socially disadvantaged populations, and transparency and completeness of
reporting of health-equity considerations in RCTs. This study can serve as a baseline assessment of the reporting of
equity considerations.
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Summary points
What is already known on the topic
 The Consolidated Reporting Standards for
Randomized Trials (CONSORT) Statement provides
a list of items that are required to be reported for all
randomized trials
 The CONSORT-Equity 2017 provides an extension
to the CONSORT Statement for transparent report-
ing of health-equity-relevant randomized trials
What this study adds
 Pilot of CONSORT-Equity items on a random sam-
ple of 200 individually and clustered equity-relevant
randomized trials, suggests that one third of the tri-
als reported subgroup analysis related to social de-
terminants of health
Background
Policy-makers in most countries have committed to re-
ducing inequalities in the Sustainable Development
Goals [1]. There is a great need for more empirical evi-
dence on efforts to redress health inequities. Health in-
equity is defined as “differences in health that are
unnecessary, avoidable, unfair, and unjust” [2]. Fairness
is a normative concept, and there are differing perspec-
tives on what is considered unfair and these may differ
across settings and time [3]. Health inequalities are con-
sidered unfair when they can be avoided, prevented, or
mitigated [4]. Not all health differences are health in-
equities; for example, age differences in Alzheimer’s dis-
ease prevalence would not be considered an age-related
inequity because the risk increases with increasing age
[5]. Also, judgments about fairness may need to take
into account opportunity costs in sectors outside of
health when redressing health inequalities.
Throughout this paper, we use the term “socially dis-
advantaged” to denote that people are disadvantaged by
differences in distribution of power and resources which
structure their living and working conditions and affect
their opportunities for health [4]. We recognize that this
terminology may be seen as labeling or stigmatizing,
which is not our intent. Some people and populations
may prefer other terms to fit their context such as
marginalized, living in a vulnerable situation or under-
served [6].
Different frameworks are available to describe factors
associated with health inequity. We use the mnemonic
PROGRESS-Plus which stands for place of residence,
race/ethnicity/culture/language, Occupation, gender/sex,
religion, education, socioeconomic status, and social
capital [7, 8]. We also recognize additional characteris-
tics as the “Plus” characteristics, such as: individual char-
acteristics (e.g., age, disability); features of relationships;
and time-dependent transitions (i.e., when a person is
temporarily at a health disadvantage) [8–10]. As stated
above, differences in health outcomes across these char-
acteristics are not always inequitable. We only consider
them to be inequities when differences in health across
these characteristics are produced or exacerbated by so-
cial disadvantage. For example, the difference in average
life expectancy across neighborhoods associated with
neighborhood-level socioeconomic deprivation in the
UK and education levels in Norway is considered in-
equitable by many [11].
Randomized controlled trials (RCTs) can provide evi-
dence about the effectiveness of an intervention and of
the effects on health equity. However, many trials do not
include people who may experience social disadvantage,
and even if they do, results are rarely disaggregated for
specific populations [3]. Under-representation of many
populations that commonly experience social disadvan-
tage has been well-documented; people living on low in-
come, ethnic minorities, women, and older adults are
often under-enrolled or excluded [12–14] despite ethical
guidelines typically stating that under-representation
should be avoided [15]. When trials do include adequate
numbers of participants representing these groups, the
authors often fail to report basic sociodemographic de-
tails, such as the socioeconomic status of participants
[16], and rarely consider subgroup hypotheses across
PROGRESS-Plus characteristics [17, 18]. Carefully
planned subgroup analyses can play a vital role in
equity-relevant trials. For example, they can be used to
investigate whether an observed total treatment effect is
consistent across subgroups in the population [19]. They
can also be used to identify subgroups with better or
worse outcomes, or those experiencing potential harms.
Pre-planned subgroup analyses can be used to test inter-
vention effects in groups specifically targeted by an
intervention, or believed to be resistant to treatment.
However, subgroup analyses are subject to multiple
methodological challenges which can complicate their
interpretation, including increased risks of type I error
due to multiple testing and low statistical power [20].
Some reviews have found that subgroup analyses are
often poorly justified, infrequently pre-specified, and in-
adequately reported [21]. While such challenges may
seem to discourage their use, lack of disaggregation or
descriptive detail means that judgments about the policy
relevance of the evidence to people who live with social
disadvantage may be difficult for decision-makers who
are using the evidence to inform and implement policies,
programs, or individual patient care. Additionally, this
lack of disaggregation limits the information available
for systematic review authors and makes it impossible to
explore differential effectiveness of the intervention.
While underpowered subgroup analyses in trials should
be interpreted with caution, they can provide useful
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information about the nature and direction of any po-
tential effect and, when combined with data from other
studies, can make more informative meta-analyses [22].
This inadequate consideration of potentially disadvan-
taged populations is often described as a limitation by
those who rely on research to make decisions concern-
ing socially disadvantaged populations [23, 24].
To address these concerns and the calls made in inter-
national public health policy documents as well as com-
mitments from research funders and journal editors
[25–28], we have developed a reporting guideline for
health-equity-relevant RCTs (CONSORT-Equity), which
aims to increase the transparency and completeness of
reporting of equity analyses to improve their usefulness
for health-equity-relevant decision making [29].
Not all published trials are relevant to decisions con-
cerning equity [3]. We define health-equity-relevant tri-
als using the following criteria:
1. Does the study include individuals or populations
who experience social disadvantage (across one or
more of PROGRESS-Plus characteristics) within the
setting and context of the study?
2. If yes, does the study assess the effects of the
intervention on the health of people who
experience social disadvantage by either:
(a). Exclusively focusing on individuals or
populations who experience social disadvantage;
or
(b). Including a heterogeneous group with
assessment of the differential impacts of the
intervention across one or more PROGRESS
characteristics?
Cluster randomized trials (CRTs), that is, trials in
which the units of randomization are coherent groups,
communities, schools, or medical practices, rather than
separate individuals, have unique methodological re-
quirements, and also, unique equity considerations [30].
They pose additional challenges for assessing effects on
health equity compared to individually randomized trials
because clusters may include individuals experiencing
different levels of social disadvantage and/or clusters
may have different experience of social disadvantage. In
addition, populations that are socially disadvantaged
across one or more PROGRESS-Plus characteristics may
be hidden within the clusters.
This study aimed to provide a descriptive assessment
of the reporting of health-equity considerations in a ran-
dom sample of 200 health-equity-relevant trials (100 in-
dividually randomized trials, RCTs and 100 CRTs). The
preliminary results of this study were used to inform the
development of the CONSORT-Equity 2017 Reporting
Guideline [29]. We also used this as an opportunity to
conduct a “baseline” assessment of the reporting of
health-equity considerations in these trials; that is, be-
fore the publication of the CONSORT-Equity 2017
guidelines, by tabulating the proportion of trials report-




This methods study was conducted as part of a larger
project to develop a reporting guideline for health-equity
relevant trials for which a protocol was published [31].
Eligibility criteria
We included a random sample of health-equity-relevant
trials (100 RCTs and 100 CRTs) using the criteria listed
in our conceptual framework (above) [3].
Individual and cluster randomized trials with primary
trial reports were eligible.
Searching
We developed a search strategy in collaboration with a
librarian scientist (JM) for health- equity-relevant trials
using both text-words and MeSH headings (Appendix
1). We tested this strategy with a reference set of 12
identified health-equity-relevant trials. The search was
modified and retested multiple times to ensure that a
sufficient number of health-equity-relevant trials were
retrieved. We searched MEDLINE, Sociological abstracts
and Econlit to encompass medical, public health, and
international development interventions. We focused on
these three major databases that were likely to include
an adequate population of equity-relevant trials from
which we could identify a sample to assess. We con-
ducted the search up to 5 May 2015 and restricted the
search to the years 2013–2015 as we were interested in
describing the most recent reporting practices.
Screening
Records were exported to Excel and sorted in random
sequence using the built-in random-number generator;
the titles and abstracts were then screened until the tar-
get sample size for RCTs and CRTs was achieved. Titles
and abstracts and the full texts of potentially health-
equity-relevant trials were screened independently, by
two researchers, using Covidence software [20]. Conflicts
were resolved through discussion at weekly team
meetings.
At the title/abstract screening phase, decisions were
based solely on whether the content of the abstract met
the eligibility criteria even though some trials may have
reported on health equity in the full text.
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Developing and testing the data extraction form
We developed and pretested a data extraction form
using Microsoft Excel (see Appendix 2 for data extrac-
tion items). Through pilot-testing, we developed a data
dictionary to ensure consistent extraction of all items
and revised this for clarification with the team.
We decided to focus on the PROGRESS characteristics
for this descriptive study. We also assessed whether the
included RCTs and CRTs reported baseline characteris-
tics for the additional PROGRESS- “Plus” characteristics.
However, we did not extract details on these “Plus” pop-
ulations nor on whether subgroup analyses were re-
ported across these “Plus” populations.
Data extraction and verification
Our extraction form was used to capture data on descriptive
characteristics including the purpose of the intervention
(whether the trial included only a socially disadvantaged
population or whether the trial included general popula-
tions in which there may be socially disadvantaged
people), and study design and characteristics of the statis-
tical analyses, including the reporting of subgroup ana-
lysis. We also collected data on whether there was any
adjustment for PROGRESS characteristics as covariates.
We assessed whether health-equity considerations were re-
ported, drawing from items from prior work on reporting
equity considerations [3, 29, 32, 33]. Details on health-
equity considerations were collected from the title/abstract,
introduction, methods, eligibility criteria, population char-
acteristics, results, subgroup analysis, interpretation of
applicability and discussion. All of these items were pre-
planned and defined (Appendix 2).
For subgroup analysis across PROGRESS characteris-
tics, we assessed the quality of reporting using the Yusuf
criteria [34]. We chose the Yusuf criteria because they
cover the important concepts from other sets of criteria
regarding the credibility of subgroup analyses [35, 36]
and we considered the criteria feasible to assess. We de-
cided a priori to not assess subgroup analyses across
additional PROGRESS-Plus characteristics, such as age
or temporary characteristics, since some of these are not
amenable to subgroup analyses (such as temporary situa-
tions). The Yusuf criteria consist of four questions:
1. Subgroup analysis pretested or planned a priori to
the study commencement
2. Hypothesis or rationale for the analysis provided
3. Statistical test for interaction performed between
the subgroups
4. Overall treatment results emphasized more than
the findings of the subgroup analysis
Data were extracted independently by two data extrac-
tors (NA, CC, ETG, MHJ, SL, SN, LSN, WM, JP, KR,
CS, SS, HS, MY) working in assigned pairs. The team of
data extractors was trained in using the data extraction
form and met weekly to discuss any clarity issues with
the data extraction items. These pairs met weekly to re-
solve conflicts and to reach consensus. When necessary,
disagreements were discussed with the broader team.
Data analysis
We used IBM SPSS Statistics (Version 25) to calculate
the frequency of reporting each item for all RCTs and
CRTs in our sample. We cross-tabulated the data for




We identified 4981 records from the search. After re-
moving duplicates, we screened 4316 records at the title
and abstract stage. We sorted all studies in random se-
quence and we screened in random sequence until the
target sample size was met. We assessed a total of 264
trials to select the first 100 RCTs and 643 trials to select
the first 100 CRTs (see Fig. 1).
Included studies
The characteristics of the included 100 CRTs and 100
RCTs are presented in Table 1. Overall, 60% (119 studies)
of the 200 included studies had an explicit health-equity
objective (64% CRTs, 55% RCTs). A third of these studies
(31%) were conducted in a resource-constrained setting as
defined by the trialists (40% CRT, 22% RCTs), of which
most were conducted in low- and middle-income coun-
tries (LMICs) (20%) (28% CRTs, 11% RCTs). The majority
of trials had interventions that focused on socially disad-
vantaged populations (overall 79%; 78% CRT, 79% RCT).
For CRTs, the majority randomized schools (27% of
CRTs), communities, or community organizations (26%),
medical practices (12%), and workplaces (3%), while the
remaining trials (32%) used “other” units of randomization
such as families, households, or geographical areas.
Reporting of health-equity considerations
The prevalence of reporting of PROGRESS characteris-
tics was similar between CRTs and RCTs (Fig. 2). Sex
was the most commonly reported characteristic (76% of
studies) (77% CRTs, 75% RCTs). The least commonly re-
ported characteristic was sexual orientation, which was
reported in 3% of studies (2% CRTs, 4% RCT). Add-
itional personal characteristics associated with health in-
equities were reported by 96% of our sample (94% CRTs,
97% RCTs). Of these additional characteristics, the most
commonly reported characteristic was age (41%).
There were few differences in reporting between RCTs
and CRTs except that 36% of CRTs reported the place
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of residence of the participants compared to 16% of RCTs.
Social capital, which we assessed as social connections be-
tween individuals within a community or household, was
reported in 20% of CRTs compared to 9% of RCTs. Social
capital was mainly operationalized as marital status. Reli-
gion was reported in 9% of CRTs and 2% of RCTs. The
higher reporting of place of residence, social capital, and
religion in CRTs vs. RCTs may be related to the need to
show whether randomization was successful in balancing
these characteristics across clusters.
Distribution of PROGRESS-Plus (place of residence,
race/ethnicity/culture/language, occupation, gender/sex,
religion, education, socioeconomic status, social capital,
and additional characteristics) and sexual orientation
considerations in 100 CRTs and 100 RCTs.
Overall, 37% of our included studies reported a sub-
group analysis across PROGRESS characteristics (25% of
CRTs, 49% of RCTs). The most commonly reported sub-
group analysis was by sex (13% CRTs, 24% RCTs),
followed by race/ethnicity/culture/language (9% overall,
5% CRTs, 13% RCTs). Other PROGRESS subgroup ana-
lyses focused on socioeconomic status (4% overall, 5%
CRTs, 3% RCTs), and place of residence (3% overall, 3%
CRTs, 2% RCTs). Subgroup analyses of other PRO-
GRESS characteristics were reported in less than 5% of
studies.
We assessed whether studies reported adjustment for
PROGRESS characteristics in their analyses. Adjustment
for these characteristics might show that data were avail-
able for disaggregated presentation of results or appro-
priate subgroup analyses; the absence of such results
might indicate a missed opportunity for equity-relevant
research. Out of all studies, 23% adjusted for gender/sex,
15% for education, 15% for race/ethnicity/culture, 4% for
socioeconomic status, and 3% for place of residence.
Less than 10% of studies adjusted for the other PRO-
GRESS characteristics in their analyses.
Overall, 71% of the included studies discussed the applic-
ability of their results with regards to one or more PRO-
GRESS characteristics (68 CRTs, 73 RCTs). In addition,
26% of those which discussed applicability (51 out of 200)
with regards to a PROGRESS characteristic also reported a
subgroup analysis across this characteristic Table 2.
For those studies with subgroup analysis, approximately
two thirds met the Yusuf criteria for quality of subgroup
analysis for pre-planned analysis (68%), rationale provided
Fig. 1 Study flow diagram. RCT randomized controlled trial, CRT cluster randomized trial
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(61%), statistical test for interaction (73%), and the overall
results emphasized more than the subgroup findings
(70%) (Table 3). Only one randomized controlled trial
(RCT) [37] and no cluster randomized controlled trials
(CRTs) mentioned whether these subgroup analyses were
informed by a-priori power calculations.
Completeness of reporting
Very few of the included studies used the term “equity” in
their title (2%). However, other terms were used in the
title such as words describing PROGRESS characteristics,
such as “low-income.” Sixty-one percent (61%) of included
trials reported on health-equity analysis or the extent of







(%) (%) N (%)
Publication year
2013 51 45 96 (48)
2014 40 49 89 (45)
2015a 9 6 15 (8)
Study had an explicit objective pertaining to equity 64 55 119 (60)
Study was reported as conducted in a resource-constrained settingb 40 22 62 (31)
Lower- or middle-income country 28 11 39 (20)
Public hospital 1 2 3 (2)
Conflict zone 1 0 1 (0.5)
Other 13 14 27 (14)
Study populationb
Students in primary or secondary school 27 11 38 (19)
Workers 3 3 6 (3)
Community members 41 36 77 (39)
Patients 19 46 65 (33)
Members of a particular professional group, such as health professionals or teachers 3 1 4 (2)
Other – 11 11 (6)
Unit of randomization
Individuals 100 100 (50)
Schools 27 27 (14)
Workplace 3 3 (2)
Community or community organization 26 26 (13)
Medical practice 12 12 (6)
Other 32 32 (16)
Participants were recruited from:
Workplace 5 1 6 (3)
School 27 10 37 (19)
Other 68 89 157 (79)
Studies that reported using special or tailored recruitment to increase enrollment of
individuals who are members of socially disadvantaged populations
11 32 43 (22)
Type of study
Focused on socially disadvantaged group 78 79 157 (79)
Universal 18 7 25 (13)
Both focused and universal 4 14 18 (9)
aThe search was conducted on 5 May 2015
bStudies could be classified as fitting more than one type of setting and more than one type of unit of randomization; therefore, numbers do not add up to 100.
RCT randomized controlled trial
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the applicability of the results across PROGRESS charac-
teristics in the abstract. Twice as many individually ran-
domized trials analyzed their results using subgroup
analysis across one or more PROGRESS characteristics
(49% compared to 25% of cluster randomized trials).
Reporting of health-equity PROGRESS characteristics
was highest in the background sections of the included
studies, with 73% of included studies describing antici-
pated differences in baseline risk or intervention accept-
ability, coverage, or effectiveness across population
subgroups defined by PROGRESS. We assessed that 60%
of these equity-relevant studies reported an explicit
objective related to health equity.
Most studies were focused on populations experiencing
social disadvantage (79%). Only 25% of studies reported
on individual or community engagement processes.
Discussion
This study was conducted to inform the development of
a reporting guideline for health-equity-relevant trials
(CONSORT-Equity) [29] and to serve as a baseline as-
sessment of quality of reporting before publication of
the CONSORT-Equity extension. The CONSORT State-
ment and its many extensions provide guidance for
reporting trials completely and transparently and the
health-equity extension focuses on items that improve
the reporting of equity-relevant trials.
In our sample of health-equity-relevant trials, 25% of
CRTs and 49% of RCTs reported a subgroup analysis by
a PROGRESS characteristic. Of these, the most com-
monly reported subgroup analysis was across sex and it
was only reported in 19% of studies (13% CRT, 24%
RCT). Other PROGRESS characteristics were assessed
using subgroup analyses in less than 10% of the studies
included in our sample. There were almost twice as
many studies which adjusted for PROGRESS characteris-
tics as studies which performed subgroup analyses.
While the approach to subgroup analysis differs across
disciplines, these studies may represent a missed oppor-
tunity for understanding effects in socially disadvantaged
populations. About two thirds of these subgroup ana-
lyses met one or more of the Yusuf criteria for quality of
subgroup analyses. Only one out of 200 trials reported
formally planning for a subgroup analysis during the
design of the trial, by considering the sample size and
power available for analysis. Because sample-size calcula-
tions are usually based on the primary comparison of
interest; that is, between treatment arms, rather than on
differential effects within subgroups, it is likely that
many studies may have been underpowered for sub-
group analyses. We believe that, even with insufficient
Fig. 2 Study baseline descriptive characteristics defined by PROGRESS characteristics
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power, if data were presented as disaggregated by im-
portant PROGRESS characteristics in all randomized tri-
als, then it could be used for hypothesis-generation for
future studies as well as in subsequent meta-analyses or
other studies where greater power could be achieved.
However, the results should be interpreted with caution
and authors should state that type-II errors are possible.
CRTs had greater prevalence of reporting baseline as-
sessment of place of residence and socioeconomic status
than RCTs, possibly because balance across these char-
acteristics is often checked to assess adequacy of cluster
randomization. However, CRTs were about half as likely
to report subgroup analyses across one or more
PROGRESS characteristics than RCTs. Possible reasons
are that CRTs have larger sample-size requirements than
RCTs and there may have been inadequate numbers of
clusters and/or participants to allow subgroup analyses
to be conducted, and because statistical analyses are
more complicated in CRTs. However, it may also be that
we found that CRTs are more likely to be focused on an
equity issue (64% compared to 55% of RCTs) and more
likely to be conducted in a resource-poor setting (40%
compared to 22%) and, therefore, conducting subgroup
analyses may have been less relevant.
Our study has some limitations. First, we selected
studies which met our criteria for being health-equity-







(%) (%) N (%)
Studies with any subgroup analysis across PROGRESS characteristics 25 49 74 (37)
Primary reported subgroup analysis across PROGRESS characteristics:
Place of residence 3 2 5 (3)
Race/ethnicity/culture 5 13 18 (9)
Occupation 0 1 1 (0.5)
Gender/sex 13 24 37 (19)
Education 1 3 4 (2)
Socioeconomic status 3 5 8 (4)
Social capital 0 1 1 (0.5)
PROGRESS characteristics adjusted for in analysis:
Place of residence 7 3 10 (5)
Race/ethnicity/culture 11 18 29 (15)
Occupation 1 5 6 (3)
Gender/sex 17 29 46 (23)
Religion 1 2 3 (2)
Education 14 15 29 (15)
Socioeconomic status 11 14 25 (13)
Social capital 0 2 2 (1)
Applicability/generalizability/external validity discussed across any PROGRESS characteristic 68 73 141 (71)
Studies that had conducted a subgroup analysis and discussed equity with regards to the
applicability of the evidence
18 33 51 (26)
Table 3 Yusuf criteria on quality of subgroup analyses (for cluster randomized controlled trials (CRTs) and randomized controlled
trials (RCTs) with subgroup analysis)






(%) (%) N (%)
Subgroup analysis pretested or planned a priori to the study commencement 68 67 50 (68)
Hypothesis or rationale for the analysis provided 60 61 45 (61)
Statistical test for interaction performed between the subgroups 80 70 54 (73)
Overall treatment results emphasized more than the findings of the subgroup analysis 64 73 52 (70)
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relevant; therefore, the study was not designed to
consider how well CONSORT-Equity items are reported
in the clinical trials’ literature in general. We did not ex-
tract descriptive information about each included study,
such as the type of intervention being assessed, so can-
not assess whether reporting is different depending on
the field of study. We have also only provided a descrip-
tion of what has been reported in these trials and we
have not made judgments about how the studies were
conducted or what should have been reported. We ex-
cluded studies at the abstract stage if they did not meet
our criteria for health-equity-relevance which may have
excluded some studies that did report on equity analyses
in the full text but not the abstract during our screening
process. This may have resulted in missing some studies
which were health-equity-relevant. It is not possible to
determine whether these would have different design or
reporting characteristics from those included in our
sample. Our search was restricted to the most recent years
(2013–2015) as we were interested in describing the most
recent reporting practices to inform the development of
the CONSORT-Equity reporting guideline. It is important
to bear in mind that the reporting of clinical trial results is
usually dictated by their study protocols, which typically
are 4 to 6 years older than the actual publication.
Therefore, we may not have captured the very latest im-
provements in methods to report health-equity-relevant
information from randomized trials. Finally, we did not as-
sess all the CONSORT-Equity items because the final ver-
sion of the equity extension was developed in 2017 after
we had completed data extraction. The items which were
not collected were added at the CONSORT-Equity meet-
ing or during the development and included items related
to eligibility, context, comparator, stratified randomisa-
tion, ethical clearance, implementation, intervention-
generated inequities and limitations (e.g., power) to assess
effects on health equity.
Our results provide a baseline estimate of the com-
pleteness of reporting of the recommended CONSORT-
Equity items. These results show that even though these
were all health-equity-relevant trials, only 73% described
a rationale for their focus on equity socially disadvan-
taged population, only 25% reported engagement with
communities or individuals who are socially disadvan-
taged, and only 20% mentioned importance of outcomes
for socially disadvantaged populations. Because
PROGRESS-Plus characteristics may be sensitive, these
findings may be limited by the information that partici-
pants were willing to disclose [38].
In this sample of health-equity-relevant trials, we
found few subgroup analyses that could inform equity
decisions. However, many more trials recorded equity-
relevant baseline descriptors, which suggests that there
was an opportunity to consider how the analyses might
inform equity considerations, including a-priori specifi-
cation of hypothesis tests about treatment effects across
relevant subgroups. Our findings concur with other
studies which have found little detail about characteris-
tics, such as gender and race/ethnicity/socioeconomic
status, in studies to inform decisions about mitigating or
redressing health inequities [16, 39–41]. The added
value of this paper is that we have identified a dearth of
studies reporting adequate consideration of relevant sub-
group hypotheses and pre-planned subgroup analyses
across several PROGRESS characteristics. This limits
their usefulness for informing decisions where health
equity is an important consideration. In addition, we
have identified deficiencies in reporting details such as
the rationale for subgroup analyses and power for these
analyses as well as details about the process of recruit-
ment, engagement with people with lived experience and
reporting of disaggregated data. This information can be
used to guide future research and research reporting.
When health-equity considerations are poorly reported
in trials, the applicability of the evidence cannot be fully
assessed, and the research will be of less value for reaching
important health-policy goals, including Sustainable Devel-
opment Goals SDG5 (gender equality) and SDG10 (in-
equality within and between countries) and the calls to
provide universal health coverage [42–46]. When these
population characteristics are adjusted for but not com-
pared, we are unable to make any conclusions about their
potential impact on differential effectiveness of the inter-
vention. This can result in a loss of important policy-
relevant or equity-relevant information. In addition, we
cannot determine whether populations are included but
hidden within trials or have purposefully been excluded or
under-represented, in which case the validity of the results
to determine prevention and care for the under-
represented groups is compromised.
Presentation of disaggregated data, accompanied by
formal subgroup analyses where appropriate, would
allow us to better understand the equity implications of
interventions. It is important to note that subgroup ana-
lyses should be carefully planned and informed by well-
formulated hypotheses: the higher the number of sub-
group analyses, the higher the risk of spurious findings
due to multiple statistical tests [47]. When planning a
trial, investigators need to consider potential population
differences in baseline risk of the condition or problem
being studied and the possibility of differential effective-
ness of the intervention and decide whether subgroup
analyses are appropriate and can be accommodated in
the sample-size calculation [48–50]. If additional sub-
group hypotheses of interest are identified during the
analyses, they should be clearly presented as exploratory
and interpreted with caution [51–53]. Presentation of
disaggregated results across relevant subgroups is
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important so that the data can be used in meta-
synthesis. Reporting needs to improve to explicitly state
and justify any pre-planned hypotheses and present re-
sults for all such analyses, describe relevant sample-size
considerations, clearly identify exploratory analyses and
their hypotheses, and report disaggregated data for rele-
vant subgroups.
One mechanism to facilitate the availability of disag-
gregated data for meta-synthesis might be to share data
in online repositories, which would allow meta-studies
to be conducted which may have greater power to detect
subgroup differences. In addition, trial registries could
request details about planned subgroup analyses and the
availability of equity variables. The CONSORT-Equity
reporting guideline aims to improve the transparency
and completeness of equity considerations in RCTs and
CRTs by providing authors with a checklist for report-
ing. However, this reporting guideline is only one step
towards more equity-relevant research which is needed
to ensure that inequities are not perpetuated or wors-
ened by programs and policies.
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